Postmenopausal osteoporosis research hub

A randomized, double-blind, parallel-group, active-controlled comparative study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of LY06006 compared with EU-Prolia in postmenopausal women with osteoporosis

This study is looking at a new medicine called LY06006 for women after menopause who have osteoporosis. It compares this new medicine to an existing one called Prolia to see if it works as well and is safe. The aim is to help make bones stronger.